Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ou MC et al. | Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure. | 1994 | Thromb. Res. | pmid:8191415 |
| Le Blanc K et al. | Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. | 1998 | Thromb. Res. | pmid:9772010 |
| Eche N et al. | Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). | 1986 | Thromb. Res. | pmid:3726808 |
| Slattery CW and Beaumont DO | Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors. | 1989 | Thromb. Res. | pmid:2554526 |
| Nguyên P et al. | Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. | 1995 | Thromb. Res. | pmid:7778064 |
| Vargaftig BB et al. | Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. | 1982 | Thromb. Res. | pmid:7164036 |
| Namm DH and High JA | Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. | 1980 | Thromb. Res. | pmid:7209881 |
| Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
| Shukla SD et al. | Hypersensitivity of diabetic human platelets to platelet activating factor. | 1992 | Thromb. Res. | pmid:1329254 |
| Westwick J et al. | Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. | 1986 | Thromb. Res. | pmid:3715810 |
| Valone FH | Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. | 1987 | Thromb. Res. | pmid:3590086 |
| Ishii H et al. | Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. | 1990 | Thromb. Res. | pmid:2382255 |
| Wade PJ et al. | Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. | 1986 | Thromb. Res. | pmid:3961730 |
| Hofmann B et al. | Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. | 1988 | Thromb. Res. | pmid:3381200 |
| Cox CP and Wood KL | Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. | 1987 | Thromb. Res. | pmid:3629553 |
| Catalán RE et al. | Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. | 1994 | Thromb. Res. | pmid:7974386 |
| Ostermann G et al. | Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. | 1987 | Thromb. Res. | pmid:3629555 |
| Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
| Glusa E et al. | Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. | 1989 | Thromb. Res. | pmid:2528843 |
| Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
| Skeaff CM and Holub BJ | The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. | 1988 | Thromb. Res. | pmid:3187952 |
| Griffin KJ and Levy JV | The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF). | 1988 | Thromb. Res. | pmid:3187959 |
| Petty AC and Scrutton MC | Platelet aggregation in whole blood: is the response to adrenaline, 5-hydroxytryptamine and PAF a direct consequence of stimulation by these agonists? | 1989 | Thromb. Res. | pmid:2749609 |
| Beaumont DO et al. | Measuring platelet function with platelet shape change, an early event in aggregation. | 1989 | Thromb. Res. | pmid:2646752 |
| Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
| Moon DG et al. | Platelet activating factor and sheep platelets: a sensitive new bioassay. | 1990 | Thromb. Res. | pmid:2326773 |
| Violi F et al. | Human platelet aggregation by PAF and thromboxane production. | 1987 | Thromb. Res. | pmid:3424290 |
| Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
| Cox CP | Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. | 1986 | Thromb. Res. | pmid:2421432 |
| Vrzheshch PV et al. | Cell response kinetics: the phenomenon of supercooperativity in aggregation of human platelets. | 1992 | Thromb. Res. | pmid:1523610 |
| Teng CM et al. | Antiplatelet actions of some coumarin compounds isolated from plant sources. | 1992 | Thromb. Res. | pmid:1523611 |
| Chlopicki S et al. | Obligatory role of lipid mediators in platelet-neutrophil adhesion. | 2003 | Thromb. Res. | pmid:14592550 |
| Kohayakawa M and Inoue K | Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. | 1986 | Thromb. Res. | pmid:3083530 |
| Tencé M et al. | Ether-phospholipid composition in neutrophils and platelets. | 1985 | Thromb. Res. | pmid:4024039 |
| Hadváry P and Baumgartner HR | Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. | 1983 | Thromb. Res. | pmid:6868019 |
| Leoncini G et al. | Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. | 1997 | Thromb. Res. | pmid:9175236 |
| Tan EL and Snyder F | Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by capillary endothelial cells isolated from rat epididymal adipose tissue. | 1985 | Thromb. Res. | pmid:4024051 |
| Despotis GJ et al. | Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. | 1997 | Thromb. Res. | pmid:9175242 |
| Ding YA et al. | Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. | 1995 | Thromb. Res. | pmid:7740521 |
| Bussolino F et al. | Intravascular release of platelet activating factor in children with sepsis. | 1987 | Thromb. Res. | pmid:3441909 |
| Ishii H et al. | A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. | 1982 | Thromb. Res. | pmid:6897588 |
| Neiman J et al. | Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. | 1989 | Thromb. Res. | pmid:2617478 |
| Pfliegler G et al. | Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. | 1993 | Thromb. Res. | pmid:8503122 |
| Altman R et al. | Why single daily dose of aspirin may not prevent platelet aggregation. | 1988 | Thromb. Res. | pmid:3140408 |
| Lukaszyk A et al. | Does acute experimental pancreatitis affect blood platelet function? | 1989 | Thromb. Res. | pmid:2524119 |
| Lecompte T et al. | Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. | 1990 | Thromb. Res. | pmid:2117306 |
| McGowan EB and Detwiler TC | Characterization of the thrombin-induced desensitization of platelet activation by thrombin. | 1983 | Thromb. Res. | pmid:6356458 |
| Mabilat-Pragnon C et al. | Urokinase localization and activity in isolated eosinophils. | 1997 | Thromb. Res. | pmid:9526961 |
| May JA et al. | Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. | 1997 | Thromb. Res. | pmid:9361371 |
| Lian EC et al. | Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. | 1984 | Thromb. Res. | pmid:6420930 |